Category Archives: Biotechnology

LAWRENCEBURG, Ind., July 9, 2012 /PRNewswire-Asia/ -- PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune(TM) nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development. Merck obtains the rights to utilize the technology with two investigational antigen-specific cancer immunotherapies which are in pre-clinical development.

Under the terms of the licensing agreement, PDS Biotechnology Corporation will receive an undisclosed upfront payment in cash, as well as development milestone payments, and commercial and sales milestone payments. PDS Biotechnology Corporation will also receive royalties on sales of the products incorporating the technology.

Dr. Frank Bedu-Addo, Chief Executive of PDS Biotechnology Corporation said, "We are very pleased that Merck which is experienced in the clinical development of cancer immunotherapies would like to utilize the Versamune(TM) technology. For PDS Biotechnology Corporation, this deal is important since the company's business strategy is focused on a few strategic out-licensing or partnering deals at a preclinical or early clinical stage. This is the stage where companies will be seeking to enhance their pipelines by taking advantage of a new technology that has broad potential applications in clinical research into the treatment and prevention of cancer and infectious diseases."

About PDS Biotechnology Corporation and Versamune(TM)

PDS Biotechnology Corporation is a privately held biotechnology company founded to exploit the newly discovered properties of specific synthetic positively charged (cationic) lipids to commercialize a new generation of immunotherapies and vaccines. The proprietary Versamune(TM) platform nanotechnology, when combined with specific cancer-associated molecules, has been demonstrated to lead to increased tumor regression rates compared to leading clinical adjuvants in pre-clinical cancer models (Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530). The Versamune(TM) nanotechnology presents a giant step forward in the development of the next generation of immunotherapies. PDS Biotechnology Corporation's lead products are being developed to treat prevalent cancers such as cervical cancer, head and neck cancer and melanoma. The technology is also being applied to the development of vaccines which are designed to protect against pandemic diseases. Visit http://www.pdsbiotech.com for more information on Versamune(TM) and products in development.

Continued here:
PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune(TM)

LAWRENCEBURG, Ind., July 9, 2012 /PRNewswire/ --PDS Biotechnology Corporation announced today that they have entered into an exclusive worldwide licensing agreement with Merck KGaA, Darmstadt, Germany, for use of PDS Biotechnology's novel Versamune nanotechnology platform in two of Merck's investigational antigen-specific cancer immunotherapies currently in pre-clinical development. Merck obtains the rights to utilize the technology with two investigational antigen-specific cancer immunotherapies which are in pre-clinical development.

Under the terms of the licensing agreement, PDS Biotechnology Corporation will receive an undisclosed upfront payment in cash, as well as development milestone payments, and commercial and sales milestone payments. PDS Biotechnology Corporation will also receive royalties on sales of the products incorporating the technology.

Dr. Frank Bedu-Addo, Chief Executive of PDS Biotechnology Corporation said, "We are very pleased that Merck which is experienced in the clinical development of cancer immunotherapies would like to utilize the Versamune technology. For PDS Biotechnology Corporation, this deal is important since the company's business strategy is focused on a few strategic out-licensing or partnering deals at a preclinical or early clinical stage. This is the stage where companies will be seeking to enhance their pipelines by taking advantage of a new technology that has broad potential applications in clinical research into the treatment and prevention of cancer and infectious diseases."

About PDS Biotechnology Corporation and VersamunePDS Biotechnology Corporation is a privately held biotechnology company founded to exploit the newly discovered properties of specific synthetic positively charged (cationic) lipids to commercialize a new generation of immunotherapies and vaccines. The proprietary Versamune platform nanotechnology, when combined with specific cancer-associated molecules, has been demonstrated to lead to increased tumor regression rates compared to leading clinical adjuvants in pre-clinical cancer models (Cancer Immunology Immunotherapy, 2008, 57: (4) 517-530). The Versamune nanotechnology presents a giant step forward in the development of the next generation of immunotherapies. PDS Biotechnology Corporation's lead products are being developed to treat prevalent cancers such as cervical cancer, head and neck cancer and melanoma. The technology is also being applied to the development of vaccines which are designed to protect against pandemic diseases. Visit http://www.pdsbiotech.com for more information on Versamune and products in development.

The rest is here:
PDS Biotechnology Corporation Signs Worldwide Licensing Agreement with Merck KGaA for Versamune™

NEW YORK, NY--(Marketwire -07/06/12)- http://www.ShinesRooms.com has a handpicked team of market professionals with over 100 years of combined investing experience. Today they are providing members comprehensive research on the Biotechnology industry and are offering free analytical research on Sequenom Inc. (SQNM) and Biogen Idec Inc. (BIIB). Register with us now to have free access to these research reports. Simply click on the link below. http://www.ShinesRooms.com/index.php?_controller=RegisterMember&_method=index

Companies in the biotechnology industry, such as Sequenom Inc. and Biogen Idec Inc. have been facing both positive and negative trends over the last little while. One major challenge over the past few years has been the huge patent cliff which has seen a large number of lucrative patents expiring. Many industry players have been struggling with shrinking revenue streams as new products are not anticipated to bring in revenues of the same magnitude. Get your free reports on Sequenom Inc. and Biogen Idec Inc. at http://www.ShinesRooms.com/index.php?_controller=RegisterMember&_method=index. There is no commitment to join.

ShinesRooms.com is the Ultimate Trading Environment for investors. If you are considering owning Sequenom Inc. and Biogen Idec Inc. then you should sign up for a free membership and our complimentary reports today. Over the last 5 years our returns outpaced any of the major indexes. Sign up today by clicking on the link below to find out what you are missing. http://www.ShinesRooms.com

Companies have been investing heavily in research and development in recent years but as time marches on, many are looking to partnerships, mergers and acquisitions as a way to access new products with lower investment in research and development. Biogen Idec is a good example of the aforementioned trend as it recently announced that it has entered into an exclusive worldwide option and collaboration agreement with Isis Pharmaceuticals Inc. to develop and commercialize a treatment for Steinert disease. Biogen Idec Inc. report is accessible for free by registering today at http://www.ShinesRooms.com/BiogenIdecInc060712.pdf

On the plus side, evolving health challenges and increasing wealth in emerging markets continue to boost demand for new therapeutics and vaccines. As a result the Biotechnology industry has largely been outpacing other markets despite continued macroeconomic volatility. Sequenom Inc. report is accessible for free by registering today at http://www.ShinesRooms.com/SequenomInc060712.pdf

The two Biotechnology stocks research reports are available for free by signing up now on the link below. http://www.ShinesRooms.com

About Shinesrooms.comShine's Rooms is the brainchild of David Shine, a 13-year Wall Street veteran with a stellar track record. For 13 years Shine has trained thousands of traders to navigate and profit from the markets. Using cutting-edge technology, Shine provides you with a community in which you can trade alongside Shine and his Team as they guide you through the market's ever-changing landscape.

To view our disclaimer, visit this link http://www.shinesrooms.com/disclaimer.html.

Read this article:
Equity Research on Sequenom Inc. and Biogen Idec Inc. -- Biotechnology Industry Taking the Good With the Bad

NEW YORK, July 4, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

India Biotechnology in India Industry

http://www.reportlinker.com/p0553099/India-Biotechnology-in-India-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Disc

This report analyzes the market for Biotechnology in India in US$ million by the following Key Sectors: Bio-Pharmaceuticals, Bio-Agriculture, Bio-Industrial, Bioinformatics, and Bio-Services. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 102 companies including many key and niche players such as Advanced Enzymes Technologies Ltd., Ajeet Seeds Ltd., Anthem BioSciences Pvt. Ltd., Bharat Biotech International Limited, Bharat Serums and Vaccines Ltd., Biocon Limited, Syngene International Limited, Dr. Reddy's Laboratories Ltd., Ecron Acunova, Eli Lilly and Company (India) Pvt. Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Indian Immunologicals Ltd., Jubilant Life Sciences Limited, Krishidhan Seeds Private Limited, Lambda Therapeutic Research Ltd., Mahyco, Max Neeman, Monsanto, Novo Nordisk India Pvt. Ltd., Novozymes South Asia Pvt. Ltd., Nuziveedu Seeds Pvt. Ltd., Ocimum Biosolutions Ltd., Panacea Biotec Ltd., Piramal Healthcare Limited, Quintiles India, Rasi Seeds (P) Ltd., Reliance Life Sciences, Serum Institute of India Ltd., Shantha Biotechnics Limited, SIRO Clinpharm, Strand Life Sciences, Veeda Clinical Research Limited, and Vimta Labs Limited. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS Study Reliability and Reporting Limitations I-1 Disclaimers I-2 Data Interpretation & Reporting Level I-2 Quantitative Techniques & Analytics I-3 Product Definition and Scope of Study I-3 Bio-Pharmaceuticals I-3 Bio-Agriculture I-3 Bio-Industrial I-3 Bioinformatics I-3 Bio-Services I-3

II. AN INDIAN MARKET REPORT

1. OUTLOOK II-1 Recession and Foreign Exchange Rate Decelerate Industry Growth II-1 Industry Emerges Strong Following Recession II-2 Brighter Prospects Ahead for the Indian Biotech Industry II-2

2. INDUSTRY OVERVIEW II-3 SWOT Analysis II-3 Diversity - Key Strength for the Industry II-4 Major Sectors in the Indian Biotechnology Industry II-4 Government Support for Biotech Innovation - A Boost for the Industry II-5 Challenges Ahead II-5 Concerted Efforts are On to Find a Way Out II-6 Major Industry-Specific Advantages of the Indian Biopharma Sector II-6 Competition II-7

Table 1: Leading Biotech Companies in India by Revenues: 2009-10 (includes corresponding Graph/Chart) II-7

Table 2: Leading Domestic Biotech Companies in India by Revenues: 2009-10 (includes corresponding Graph/Chart) II-8 Exports - A Major Market for Indian Biotech Industry II-8

Read more from the original source:
India Biotechnology in India Industry

Ibadan Stakeholders including members of the National Assembly have berated President Goodluck Jonathan over his inability to assent into law till date the agricultural biotechnology bill which was passed by the 6th National Assembly since June 2011.

The chairman, Senate Committee on Capital Market, Senator Ayo Adeseun and the chairman, House of Representatives Committee on Science and Technology, Abiodun Akinlade were among the stakeholders who met at the June Edition of the Open Forum on Agricultural Biotechnology (OPAB) in Ibadan.

The legislators expressed their displeasure over the inability of the President to ascent to the bill one year after it was passed by both chambers of the National Assembly.

The forum which drew agricultural professionals from different parts of the country including chief executives of the various research institutions had the theme "Biotechnology for improved Cocoa Production in Nigeria."

In an address, the governor of Oyo State, Senator Isiaka Abiola Ajimobi, noted that "the domestication of biotechnology in Nigeria is a welcome development in view of the vital role it can play in the socio-economic development of the nation, including environment and agriculture, as evidenced from development in other climes the world over."

The governor was represented by his Deputy, Chief Moses Alake Adeyemo.

Senator Adeseun, in his contribution, lamented that President Goodluck Jonathan was yet to sign into law several bills passed by the National Assembly, notably the agricultural biotechnology bill, emphasizing that this has been impacting negatively on the envisaged success of the much publicized agricultural transformation agenda of the present administration.

"Nigeria, despite its rich agricultural endowment has been importing an equivalent of one billion naira worth of rice per day, apart from other similar food importations," Adeseun said.

He was optimistic the the massive importation trend would change through the adoption of biotechnology.

He said: "In any case, if he (President Jonathan) fails to assent the Agricultural Biotechnology Bill, it is a matter of time we in the National Assembly will now assume that he has veto the bill and we will bring it back and we will override his veto."

See the original post here:
Nigeria: Stakeholders Challenge Jonathan Over Agricultural Biotechnology Law

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/9kv7j8/uk_biotechnology_s) has announced the addition of the "UK Biotechnology Sector: Industry Profile" report to their offering.

This industry profile helps to gain an insight into the evolution of the industry and competitive dynamics prevalent in the market. It discusses the significant developments in the industry and analyzes the key trends and issues. The profile provides inputs in strategic business planning of industry professionals.

This profile is of immense help to management consultants, analysts, market research organizations and corporate advisors.

Key Topics Covered

Industry Snapshot

This section gives a holistic overview of the industry. It starts with defining the market and goes on to give historical and current market size figures. It also clearly illustrates the major segments of the market which would be discussed later on in the report.

Industry Analysis

It involves a comprehensive analysis of the industry and its market segments. This section discusses the key developments that have taken place in the industry. It also identifies and analyzes the driving factors and challenges of the industry. A description of the regulatory structure tells us about the major regulatory bodies, laws and government policies.

Country Analysis

More:
Research and Markets: UK Biotechnology Sector: Industry Profile